The news: The generic GLP-1 diabetes and weight loss drug market outside the US is accelerating; multiple companies have been approved to sell generic semaglutide in India following the March expiration of Novo Nordisk’s Ozempic and Wegovy patents there.

• Dr. Reddy’s plans to launch its generic semaglutide in India at 50% to 60% below brand drug counterparts, per Reuters. Its generic Ozempic (Ampic) has been approved, while approval for its generic Wegovy is still pending.
• India’s largest drugmaker, Sun Pharma, will also market its approved semaglutide products for diabetes and obesity in the country, alongside at least seven other drugmakers with injectable and oral versions.

Why it matters: The launch of India’s generic semaglutide signals global GLP-1 pricing and competition, especially as Novo’s semaglutide also faces patent losses in Canada, China and Brazil.

India’s generic semaglutide could reset global pricing expectations. Steep discounts of 50% or more establish lower price benchmarks in a category projected to reach $80 billion to $100 billion by 2030, strengthening payer leverage in other markets and putting pressure on Novo, Eli Lilly, and emerging GLP-1 competitors.

Cheaper generic GLP-1s may compress long-term market value—even if access expands. Lower-cost versions can drive volume growth in high-need markets, but faster-than-expected price erosion across multiple countries could reduce the category’s overall revenue potential and raise the bar for next-generation obesity drugs to justify premium pricing.

Implications for pharma marketers: Inexpensive generic versions of Ozempic and Wegovy outside the US don't just erode brands' global revenue, but also reset expectations about costs for this class of drugs. As lower-cost semaglutide generics expand internationally, premium GLP-1 brands will need stronger differentiation to defend pricing, like emphasizing superior outcomes, real-world evidence, and convenience.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.